Burden of Fatigue Among Patients with Ulcerative Colitis and Crohn’s Disease: Results from a Global Survey of Patients and Gastroenterologists

Abstract

Introduction To assess the prevalence of fatigue and its association with disease activity and patient-reported outcomes among patients with ulcerative colitis (UC) or Crohn’s disease (CD). Methods Data from a cross-sectional survey conducted with gastroenterologists and their consulting adult patients with UC or CD were analyzed. Data were collected via gastroenterologist-completed patient record forms and patient-self completion forms. Patient demographics, clinical characteristics, disease activity and medication use were reported by the gastroenterologist, while current symptoms (fatigue, rectal urgency, abdominal pain, sleep disturbance), work productivity and the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) were reported by the patient. Logistic regression models were used to identify measures associated with fatigue and expressed as odds ratio (OR) with 95% confidence interval. p < 0.05 was considered statistically significant. Results A total of 1057 patients with UC and 1228 patients with CD were included in this analysis. Fatigue was reported in 22.6% of UC and 26.0% of patients with CD. Higher proportion of patients with UC and fatigue had moderate/severe disease activity ( p = 0.0001), had a higher Mayo score (5.0 vs. 4.0, p < 0.0001) and were unemployed (5.6% vs. 3.9%, p = 0.0149) compared to those without fatigue. In patients with CD reporting fatigue, a higher proportion were female (55.9% vs. 48.2%, p = 0.0193), were unemployed (5.8% vs. 4.9%, p = 0.0069), had moderate/severe disease ( p < 0.0001) and had a higher mean Crohn’s Disease Activity Index score (145.0 vs. 96.2, p < 0.0001) than patients without fatigue. Patients with UC and fatigue had higher mean level of pain ( p < 0.0001) and sleep disturbance ( p < 0.0001), whereas patients with CD and fatigue had lower SIBDQ scores ( p < 0.0001) and greater work impairment ( p = 0.0015) than patients without fatigue. Abdominal pain (OR: 2.01, p = 0.001) and use of immunomodulators (OR: 1.69, p = 0.006) increased the odds of having fatigue in patients with UC. In patients with CD, abdominal pain (OR: 2.29, p < 0.001) and use of biologics or biosimilars (OR: 2.02, p = 0.003) increased the odds of having fatigue. Conclusion Fatigue is a common symptom among patients with UC or CD that is associated with higher levels of disease activity and decreased work productivity and is driven by various factors. A multidisciplinary approach may be needed to manage fatigue.

Effect of Health Maintenance Program Related to Ulcerative Colitis on Selected Patient’s Outcomes during Remission Phase

“…For correlation between simple clinical colitis activity, fatigue severity and quality of life on post program, the present study clarified that there was a significant positive correlation between simple clinical colitis activity and fatigue severity among the study group. This result was in accordance with Regueiro et al, (2023) who found that there was a significant positive relationship between clinical disease activity and fatigue. A higher percentage of patients with UC and fatigue had moderate/severe clinical disease activity.…”

Volume and Distribution of White Matter Hyperintensities in Rheumatoid Arthritis and Ulcerative Colitis Patients

“…Fatigue is a prominent feature of autoimmune diseases and is a large area of focus in rheumatoid arthritis (RA) and ulcerative colitis (UC) research [1, 2]. There is an extensive body of previously published work exploring neuroimaging in these chronic inflammatory diseases looking to identify surrogate biomarkers of disease linked to fatigue [3].…”

Protective effect of five-flavor sophora flavescens enteric-coated capsules on inflammatory bowel disease and its molecular mechanism

“…Ulcerative colitis (UC), also known as chronic non-specific UC, is an unexplained rectal and colitis lesion, which has been classified as one of the modern refractory diseases by the world Health Organization (WHO) and seriously affects the normal life of patients (Regueiro et al, 2023). Clinically, it is mainly characterized by recurrent abdominal pain, diarrhea, mucopurulent bloody stools, tenesmus and so on.…”